WO2002000897A3 - Novel chimeric promoters - Google Patents

Novel chimeric promoters Download PDF

Info

Publication number
WO2002000897A3
WO2002000897A3 PCT/US2001/020123 US0120123W WO0200897A3 WO 2002000897 A3 WO2002000897 A3 WO 2002000897A3 US 0120123 W US0120123 W US 0120123W WO 0200897 A3 WO0200897 A3 WO 0200897A3
Authority
WO
WIPO (PCT)
Prior art keywords
novel chimeric
chimeric promoters
enhancers
chimeric promoter
novel
Prior art date
Application number
PCT/US2001/020123
Other languages
French (fr)
Other versions
WO2002000897A2 (en
Inventor
Juha Punnonen
Anne Wright
Andrey Semyonov
Original Assignee
Maxygen Inc
Juha Punnonen
Anne Wright
Andrey Semyonov
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Maxygen Inc, Juha Punnonen, Anne Wright, Andrey Semyonov filed Critical Maxygen Inc
Priority to AU2001268716A priority Critical patent/AU2001268716A1/en
Priority to EP01946703A priority patent/EP1297146A2/en
Publication of WO2002000897A2 publication Critical patent/WO2002000897A2/en
Publication of WO2002000897A3 publication Critical patent/WO2002000897A3/en

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N15/00—Mutation or genetic engineering; DNA or RNA concerning genetic engineering, vectors, e.g. plasmids, or their isolation, preparation or purification; Use of hosts therefor
    • C12N15/09—Recombinant DNA-technology
    • C12N15/10—Processes for the isolation, preparation or purification of DNA or RNA
    • C12N15/1034—Isolating an individual clone by screening libraries
    • C12N15/1058—Directional evolution of libraries, e.g. evolution of libraries is achieved by mutagenesis and screening or selection of mixed population of organisms
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N15/00—Mutation or genetic engineering; DNA or RNA concerning genetic engineering, vectors, e.g. plasmids, or their isolation, preparation or purification; Use of hosts therefor
    • C12N15/09—Recombinant DNA-technology
    • C12N15/10—Processes for the isolation, preparation or purification of DNA or RNA
    • C12N15/1034—Isolating an individual clone by screening libraries
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N15/00—Mutation or genetic engineering; DNA or RNA concerning genetic engineering, vectors, e.g. plasmids, or their isolation, preparation or purification; Use of hosts therefor
    • C12N15/09—Recombinant DNA-technology
    • C12N15/10—Processes for the isolation, preparation or purification of DNA or RNA
    • C12N15/1034—Isolating an individual clone by screening libraries
    • C12N15/1086—Preparation or screening of expression libraries, e.g. reporter assays
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N15/00—Mutation or genetic engineering; DNA or RNA concerning genetic engineering, vectors, e.g. plasmids, or their isolation, preparation or purification; Use of hosts therefor
    • C12N15/09—Recombinant DNA-technology
    • C12N15/63—Introduction of foreign genetic material using vectors; Vectors; Use of hosts therefor; Regulation of expression
    • C12N15/67—General methods for enhancing the expression
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N15/00—Mutation or genetic engineering; DNA or RNA concerning genetic engineering, vectors, e.g. plasmids, or their isolation, preparation or purification; Use of hosts therefor
    • C12N15/09—Recombinant DNA-technology
    • C12N15/63—Introduction of foreign genetic material using vectors; Vectors; Use of hosts therefor; Regulation of expression
    • C12N15/79—Vectors or expression systems specially adapted for eukaryotic hosts
    • C12N15/85—Vectors or expression systems specially adapted for eukaryotic hosts for animal cells
    • G—PHYSICS
    • G16—INFORMATION AND COMMUNICATION TECHNOLOGY [ICT] SPECIALLY ADAPTED FOR SPECIFIC APPLICATION FIELDS
    • G16B—BIOINFORMATICS, i.e. INFORMATION AND COMMUNICATION TECHNOLOGY [ICT] SPECIALLY ADAPTED FOR GENETIC OR PROTEIN-RELATED DATA PROCESSING IN COMPUTATIONAL MOLECULAR BIOLOGY
    • G16B30/00—ICT specially adapted for sequence analysis involving nucleotides or amino acids
    • G16B30/10—Sequence alignment; Homology search
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N2800/00—Nucleic acids vectors
    • C12N2800/10—Plasmid DNA
    • C12N2800/108—Plasmid DNA episomal vectors
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12Q—MEASURING OR TESTING PROCESSES INVOLVING ENZYMES, NUCLEIC ACIDS OR MICROORGANISMS; COMPOSITIONS OR TEST PAPERS THEREFOR; PROCESSES OF PREPARING SUCH COMPOSITIONS; CONDITION-RESPONSIVE CONTROL IN MICROBIOLOGICAL OR ENZYMOLOGICAL PROCESSES
    • C12Q1/00—Measuring or testing processes involving enzymes, nucleic acids or microorganisms; Compositions therefor; Processes of preparing such compositions
    • C12Q1/68—Measuring or testing processes involving enzymes, nucleic acids or microorganisms; Compositions therefor; Processes of preparing such compositions involving nucleic acids
    • C12Q1/6813—Hybridisation assays
    • C12Q1/6834—Enzymatic or biochemical coupling of nucleic acids to a solid phase
    • C12Q1/6837—Enzymatic or biochemical coupling of nucleic acids to a solid phase using probe arrays or probe chips
    • G—PHYSICS
    • G16—INFORMATION AND COMMUNICATION TECHNOLOGY [ICT] SPECIALLY ADAPTED FOR SPECIFIC APPLICATION FIELDS
    • G16B—BIOINFORMATICS, i.e. INFORMATION AND COMMUNICATION TECHNOLOGY [ICT] SPECIALLY ADAPTED FOR GENETIC OR PROTEIN-RELATED DATA PROCESSING IN COMPUTATIONAL MOLECULAR BIOLOGY
    • G16B30/00—ICT specially adapted for sequence analysis involving nucleotides or amino acids
    • Y—GENERAL TAGGING OF NEW TECHNOLOGICAL DEVELOPMENTS; GENERAL TAGGING OF CROSS-SECTIONAL TECHNOLOGIES SPANNING OVER SEVERAL SECTIONS OF THE IPC; TECHNICAL SUBJECTS COVERED BY FORMER USPC CROSS-REFERENCE ART COLLECTIONS [XRACs] AND DIGESTS
    • Y02—TECHNOLOGIES OR APPLICATIONS FOR MITIGATION OR ADAPTATION AGAINST CLIMATE CHANGE
    • Y02A—TECHNOLOGIES FOR ADAPTATION TO CLIMATE CHANGE
    • Y02A50/00—TECHNOLOGIES FOR ADAPTATION TO CLIMATE CHANGE in human health protection, e.g. against extreme weather
    • Y02A50/30—Against vector-borne diseases, e.g. mosquito-borne, fly-borne, tick-borne or waterborne diseases whose impact is exacerbated by climate change

Abstract

The invention provides novel chimeric promoter/enhancers. The chimeric promoter/enhancers are particularly suitable for directing gene expression in mammalian cells.
PCT/US2001/020123 2000-06-23 2001-06-21 Novel chimeric promoters WO2002000897A2 (en)

Priority Applications (2)

Application Number Priority Date Filing Date Title
AU2001268716A AU2001268716A1 (en) 2000-06-23 2001-06-21 Novel chimeric promoters
EP01946703A EP1297146A2 (en) 2000-06-23 2001-06-21 Novel chimeric promoters

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
US21382900P 2000-06-23 2000-06-23
US60/213,829 2000-06-23

Publications (2)

Publication Number Publication Date
WO2002000897A2 WO2002000897A2 (en) 2002-01-03
WO2002000897A3 true WO2002000897A3 (en) 2002-08-15

Family

ID=22796670

Family Applications (1)

Application Number Title Priority Date Filing Date
PCT/US2001/020123 WO2002000897A2 (en) 2000-06-23 2001-06-21 Novel chimeric promoters

Country Status (4)

Country Link
US (1) US7074590B2 (en)
EP (1) EP1297146A2 (en)
AU (1) AU2001268716A1 (en)
WO (1) WO2002000897A2 (en)

Families Citing this family (6)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US7134459B2 (en) * 2003-06-12 2006-11-14 Symyx Technologies, Inc. Methods and apparatus for mixing powdered samples
US20070178505A1 (en) * 2006-01-03 2007-08-02 Curt Fischer Promoter engineering and genetic control
GB0606190D0 (en) 2006-03-28 2006-05-10 Isis Innovation Construct
JP5298134B2 (en) 2007-11-01 2013-09-25 パーシード セラピューティクス リミテッド ライアビリティ カンパニー Immunosuppressive polypeptides and nucleic acids
KR100958293B1 (en) * 2008-03-27 2010-05-19 단국대학교 산학협력단 Allosteric trans?splicing group I ribozyme whose activity of target-specific RNA replacement is controlled by theophylline
ES2540753T3 (en) * 2012-09-24 2015-07-13 Lonza Biologics Plc. Expression vectors comprising cytomegalovirus promoter and amplifier chimeric sequences

Citations (1)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US5641665A (en) * 1994-11-28 1997-06-24 Vical Incorporated Plasmids suitable for IL-2 expression

Family Cites Families (69)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US4762780A (en) 1984-04-17 1988-08-09 The Regents Of The University Of California Method and composition for screening and diagnosing "HCMV"
DE3431140A1 (en) 1984-08-24 1986-03-06 Behringwerke Ag, 3550 Marburg ENHANCER FOR EUKARYOTIC EXPRESSION SYSTEMS
CA1341482C (en) 1984-10-31 2005-05-10 Paul A. Luciw Process for preparing fragments of aids-associated retroviruses
US5168062A (en) 1985-01-30 1992-12-01 University Of Iowa Research Foundation Transfer vectors and microorganisms containing human cytomegalovirus immediate-early promoter-regulatory DNA sequence
US5866363A (en) 1985-08-28 1999-02-02 Pieczenik; George Method and means for sorting and identifying biological information
US4968615A (en) 1985-12-18 1990-11-06 Ciba-Geigy Corporation Deoxyribonucleic acid segment from a virus
US4963481A (en) 1985-12-18 1990-10-16 Genetics Institute Inc Promoter system
US5824469A (en) 1986-07-17 1998-10-20 University Of Washington Method for producing novel DNA sequences with biological activity
US5273876A (en) 1987-06-26 1993-12-28 Syntro Corporation Recombinant human cytomegalovirus containing foreign gene
GB8717430D0 (en) 1987-07-23 1987-08-26 Celltech Ltd Recombinant dna product
US5512463A (en) 1991-04-26 1996-04-30 Eli Lilly And Company Enzymatic inverse polymerase chain reaction library mutagenesis
US5834252A (en) 1995-04-18 1998-11-10 Glaxo Group Limited End-complementary polymerase reaction
US5837458A (en) 1994-02-17 1998-11-17 Maxygen, Inc. Methods and compositions for cellular and metabolic engineering
US6165793A (en) 1996-03-25 2000-12-26 Maxygen, Inc. Methods for generating polynucleotides having desired characteristics by iterative selection and recombination
US5605793A (en) 1994-02-17 1997-02-25 Affymax Technologies N.V. Methods for in vitro recombination
US6335160B1 (en) 1995-02-17 2002-01-01 Maxygen, Inc. Methods and compositions for polypeptide engineering
US6117679A (en) 1994-02-17 2000-09-12 Maxygen, Inc. Methods for generating polynucleotides having desired characteristics by iterative selection and recombination
US5928905A (en) 1995-04-18 1999-07-27 Glaxo Group Limited End-complementary polymerase reaction
US5514588A (en) 1994-12-13 1996-05-07 Exxon Research And Engineering Company Surfactant-nutrients for bioremediation of hydrocarbon contaminated soils and water
US5958672A (en) 1995-07-18 1999-09-28 Diversa Corporation Protein activity screening of clones having DNA from uncultivated microorganisms
US6057103A (en) 1995-07-18 2000-05-02 Diversa Corporation Screening for novel bioactivities
US6030779A (en) 1995-07-18 2000-02-29 Diversa Corporation Screening for novel bioactivities
US6168919B1 (en) 1996-07-17 2001-01-02 Diversa Corporation Screening methods for enzymes and enzyme kits
US6004788A (en) 1995-07-18 1999-12-21 Diversa Corporation Enzyme kits and libraries
US6117676A (en) * 1995-07-27 2000-09-12 Srl, Inc. Transfected human amniotic cells and method for producing a gene product
WO1997007206A1 (en) 1995-08-11 1997-02-27 Okkels, Jens, Sigurd Method for preparing polypeptide variants
US5962258A (en) 1995-08-23 1999-10-05 Diversa Corporation Carboxymethyl cellulase fromthermotoga maritima
US6489145B1 (en) 1996-07-09 2002-12-03 Diversa Corporation Method of DNA shuffling
US5939250A (en) 1995-12-07 1999-08-17 Diversa Corporation Production of enzymes having desired activities by mutagenesis
US5814473A (en) 1996-02-09 1998-09-29 Diversa Corporation Transaminases and aminotransferases
US6171820B1 (en) 1995-12-07 2001-01-09 Diversa Corporation Saturation mutagenesis in directed evolution
US5962283A (en) 1995-12-07 1999-10-05 Diversa Corporation Transminases and amnotransferases
US6238884B1 (en) 1995-12-07 2001-05-29 Diversa Corporation End selection in directed evolution
US20030215798A1 (en) 1997-06-16 2003-11-20 Diversa Corporation High throughput fluorescence-based screening for novel enzymes
US5830696A (en) 1996-12-05 1998-11-03 Diversa Corporation Directed evolution of thermophilic enzymes
US5965408A (en) 1996-07-09 1999-10-12 Diversa Corporation Method of DNA reassembly by interrupting synthesis
AU1367897A (en) 1996-01-10 1997-08-01 Novo Nordisk A/S A method for in vivo production of a mutant library in cells
US5942430A (en) 1996-02-16 1999-08-24 Diversa Corporation Esterases
US5958751A (en) 1996-03-08 1999-09-28 Diversa Corporation α-galactosidase
US6096548A (en) 1996-03-25 2000-08-01 Maxygen, Inc. Method for directing evolution of a virus
US5789228A (en) 1996-05-22 1998-08-04 Diversa Corporation Endoglucanases
AU3571797A (en) 1996-06-17 1998-01-07 Fox Chase Cancer Center Nucleic acid molecule for enhancing gene expression
US5877001A (en) 1996-06-17 1999-03-02 Diverso Corporation Amidase
US5763239A (en) 1996-06-18 1998-06-09 Diversa Corporation Production and use of normalized DNA libraries
CA2257863A1 (en) 1996-06-19 1997-12-24 Diversa Corporation Thermostable phosphatases
US5939300A (en) 1996-07-03 1999-08-17 Diversa Corporation Catalases
US6156567A (en) 1996-07-03 2000-12-05 Merial Truncated transcriptionally active cytomegalovirus promoters
JP2001504325A (en) 1996-09-27 2001-04-03 マキシジェン，インコーポレイテッド A method for optimization of gene therapy by recursive sequence shuffling and selection
EP0963434A4 (en) 1996-09-27 2000-10-25 Maxygen Inc Methods for optimization of gene therapy by recursive sequence shuffling and selection
US6200959B1 (en) * 1996-12-04 2001-03-13 Powerject Vaccines Inc. Genetic induction of anti-viral immune response and genetic vaccine for filovirus
DE69733322T2 (en) 1996-12-06 2006-02-02 Diversa Corp., San Diego Glycosidase ENZYMES
WO1998028416A1 (en) 1996-12-20 1998-07-02 Novo Nordisk A/S In vivo recombination
KR100570935B1 (en) 1997-01-17 2006-04-13 맥시겐, 인크. Evolution of whole cells and organisms by recursive sequence recombination
CN1252100A (en) 1997-02-13 2000-05-03 唐化学原料公司 Recombinant haloaliphatic dehalogenases
DK1015575T3 (en) 1997-03-18 2010-08-23 Novozymes As Shuffling of heterologous DNA sequences
DE69840382D1 (en) 1997-03-18 2009-02-05 Novozymes As METHOD FOR THE PRODUCTION OF A LIBRARY THROUGH DNA SHUFFLING
KR20000076363A (en) 1997-03-18 2000-12-26 한센 핀 베네드, 안네 제헤르, 웨이콥 마리안느 An in vitro method for construction of a dna library
US6153410A (en) 1997-03-25 2000-11-28 California Institute Of Technology Recombination of polynucleotide sequences using random or defined primers
DE69826604D1 (en) 1997-04-22 2004-11-04 Gist Brocades Bv METHOD FOR THE FERMENTATIVE PRODUCTION OF DEACYLATED CEPHALOSPORINES
US5948666A (en) 1997-08-06 1999-09-07 Diversa Corporation Isolation and identification of polymerases
US5876997A (en) 1997-08-13 1999-03-02 Diversa Corporation Phytase
US6610528B1 (en) 1997-08-26 2003-08-26 Diversa Corporation Microbial enrichment using a container having a plurality of solid support particles
CA2315819A1 (en) 1997-10-15 1999-04-22 Diversa Corporation Screening for novel compounds which regulate biological interactions
WO1999021979A1 (en) 1997-10-28 1999-05-06 Maxygen, Inc. Human papillomavirus vectors
EP1030861A4 (en) 1997-10-31 2001-09-05 Maxygen Inc Modification of virus tropism and host range by viral genome shuffling
KR20010032861A (en) 1997-12-08 2001-04-25 캘리포니아 인스티튜트 오브 테크놀로지 Method for creating polynucleotide and polypeptide sequences
EP0977895A1 (en) 1997-12-30 2000-02-09 MARTIN, William John Stealth virus nucleic acids and related methods
EP1045919A1 (en) 1998-01-16 2000-10-25 Genzyme Corporation Novel promoter elements for persistent gene expression
JP2002507392A (en) 1998-02-11 2002-03-12 マキシジェン， インコーポレイテッド Optimization of immunomodulatory properties of gene vaccines

Patent Citations (1)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US5641665A (en) * 1994-11-28 1997-06-24 Vical Incorporated Plasmids suitable for IL-2 expression

Non-Patent Citations (3)

* Cited by examiner, † Cited by third party
Title
ALCENDOR D.J. ET AL.: "Analysis of the Rhesus cytomegalovirus Immeadiate-Early gene promoter", VIROLOGY, vol. 194, 1993, pages 815 - 821, XP002198528 *
CHAPMAN B S ET AL: "EFFECT OF INTRON A FROM HUMAN CYTOMEGALOVIRUS (TOWNE) IMMEDIATE- EARLY GENE ON HETEROLOGOUS EXPRESSION IN MAMMALIAN CELLS", NUCLEIC ACIDS RESEARCH, OXFORD UNIVERSITY PRESS, SURREY, GB, vol. 19, no. 14, 25 July 1991 (1991-07-25), pages 3979 - 3986, XP000569788, ISSN: 0305-1048 *
DATABASE GENBANK [online] 10 February 1999 (1999-02-10), "Human cytomegalovirus strain AD169 complete genome.", XP002198529, Database accession no. X17403 *

Also Published As

Publication number Publication date
US7074590B2 (en) 2006-07-11
WO2002000897A2 (en) 2002-01-03
EP1297146A2 (en) 2003-04-02
AU2001268716A1 (en) 2002-01-08
US20020081708A1 (en) 2002-06-27

Similar Documents

Publication Publication Date Title
AU2433901A (en) Chimeric natriuretic peptides
EP2345671B8 (en) Optimized fc variants and methods for their generation
AU1292700A (en) Immune cells having predefined biological specificity, comprising chimeric t cell receptor
AU2002236096A1 (en) Salmonella promoter for heterologous gene expression
AU3358999A (en) Chimeric adenoviral vectors for targeted gene delivery
AU7131600A (en) Acid-inducible promoters for gene expression
ZA9810915B (en) Optimization of cells for endogenous gene activation.
WO2004005221A3 (en) Benzoate- and anthranilate-inducible promoters
AU2001241682A1 (en) Gene expression system based on chimeric receptors
WO2002000897A3 (en) Novel chimeric promoters
WO2001049721A3 (en) Bacterial genes and proteins that are essential for cell viability and their uses
WO2000004051A3 (en) Growth differentiation factor promoter and uses therefor
WO2002031121A3 (en) Improvement of endothelial cell-cell cohesion
AU2001247467A1 (en) Peptides targeting specifically tumor-derived endothelial cells
AU2001278700A1 (en) Method of culturing human chondrocytes
AU2001266740A1 (en) Promoters for regulated gene expression
AU7116700A (en) Thermus promoters for gene expression
AU2001270614A1 (en) Chimeric promoters for controlling expression in smooth muscle cells
EP1048733A3 (en) Plant promoters
AU2003241299A1 (en) Novel prostate tumor-specific promoter
AU5561599A (en) Dna promoter sequence for gene expression
AU2003261922A1 (en) Secretory or membrane-binding chimeric protein
IL142680A0 (en) Minimal promoters and uses thereof
ZA200408194B (en) Recombinant yeast cells increasing the synthesis of resveratrol during fermentation.
AU2003282465A8 (en) Isolated mammalian membrane protein genes

Legal Events

Date Code Title Description
AK Designated states

Kind code of ref document: A2

Designated state(s): AE AG AL AM AT AU AZ BA BB BG BR BY BZ CA CH CN CO CR CU CZ DE DK DM DZ EE ES FI GB GD GE GH GM HR HU ID IL IN IS JP KE KG KP KR KZ LC LK LR LS LT LU LV MA MD MG MK MN MW MX MZ NO NZ PL PT RO RU SD SE SG SI SK SL TJ TM TR TT TZ UA UG US UZ VN YU ZA ZW

AL Designated countries for regional patents

Kind code of ref document: A2

Designated state(s): GH GM KE LS MW MZ SD SL SZ TZ UG ZW AM AZ BY KG KZ MD RU TJ TM AT BE CH CY DE DK ES FI FR GB GR IE IT LU MC NL PT SE TR BF BJ CF CG CI CM GA GN GW ML MR NE SN TD TG

121 Ep: the epo has been informed by wipo that ep was designated in this application
DFPE Request for preliminary examination filed prior to expiration of 19th month from priority date (pct application filed before 20040101)
WWE Wipo information: entry into national phase

Ref document number: 2001946703

Country of ref document: EP

WWP Wipo information: published in national office

Ref document number: 2001946703

Country of ref document: EP

REG Reference to national code

Ref country code: DE

Ref legal event code: 8642

NENP Non-entry into the national phase

Ref country code: JP

WWW Wipo information: withdrawn in national office

Ref document number: 2001946703

Country of ref document: EP